Advertisement

Topics

Context Therapeutics Initiates Collaborations with Three Leading Research Partners on the Biology of Sigma1

06:00 EDT 17 Aug 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Institutions to Conduct Disease-Specific Pre-clinical Studies with the Company’s Proprietary Investigational Compounds Context Therapeutics, a biotechnology company dedicated to creating new medicines for cancer, fibrosis,...

Other Sources for this Article

Context Therapeutics
Martin Lehr
Chief Executive Officer
info@contexttherapeutics.com

NEXT ARTICLE

More From BioPortfolio on "Context Therapeutics Initiates Collaborations with Three Leading Research Partners on the Biology of Sigma1"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...